14 results
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
in HIV-AIDS Preventing ... amphotericin B, 3 to 5 mg/kg ... #Treatment #management ... #opportunistic ... #pharmacology
IDSA Recommendations for Preventing and Treating Chagas Disease (American Trypanosomiasis) in HIV-AIDS
Preventing Clinical Disease
Indication:  Individuals
Nifurtimox 8–10 mg/kg ... #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
Leishmaniasis #Prevention ... #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
Peritoneal Dialysis vs Hemodialysis - Advantages and Disadvantages 
Peritoneal Dialysis:
 • Access: Abdominal wall insertion of
Hemodialysis - Advantages ... thrombosis or infection ... #Hemodialysis #comparison ... #table #advantages ... disadvantages #nephrology #management
IDSA Recommendations for Treating Cytomegalovirus Infections in HIV-AIDS
Preventing CMV Disease:
 • CMV end-organ disease is best
in HIV-AIDS Preventing ... other factors (e.g ... #Treatment #management ... #opportunistic ... #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
mucosal #IDSA #Prevention ... #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Coccidiodomycosis in HIV-AIDS
Treating Mild Infections (Such As Focal Pneumonia or asymptomatic patients
amphotericin B 3–5 mg/kg ... Coccidiodomycosis #IDSA #Prevention ... #Treatment #management ... #opportunistic ... #pharmacology
IDSA Recommendations for Preventing and Treating Histoplasma Capsulatum Infections in HIV-AIDS
Indications for Initiating Primary Prophylaxis:
 •
Recommendations for Preventing ... with ARV (see Table ... #Treatment #management ... #opportunistic ... #pharmacology
IDSA Recommendations for Treating Herpes Simplex Virus (HSV) Infections in HIV-AIDS
Treating Orolabial Lesions (Duration: 5–10 days)
acyclovir 5 mg/kg ... HerpesSimplex #HSV #IDSA #Prevention ... #Treatment #management ... #opportunistic ... #pharmacology
IDSA Recommendations for Preventing and Treating Cryptococcosis in HIV-AIDS
Treatment for cryptococcosis consists of 3 phases: induction,
Recommendations for Preventing ... #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology